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The influence of dietary conditions in the effects
of resveratrol on hepatic steatosis
I. Milton-Laskibar, a,b,c L. Aguirre, *a,b,c S. Gómez-Zorita, a,b,c A. P. Rolo d,e
and M. P. Portillo a,b,c
Non-alcoholic fatty liver disease (NAFLD) is considered the major cause for the development of chronic
liver alterations. Hepatic steatosis is the most benign and common form of NAFLD, although its potential
to evolve into more detrimental liver alterations makes its treatment necessary. In this regard, much atten-
tion has been paid to polyphenols, with resveratrol being one of the most studied ones. This review is
aimed at studying the effects induced by resveratrol on hepatic steatosis in both preclinical studies con-
ducted under different feeding conditions (overfeeding, normal feeding and caloric restriction), and in
clinical trials. The vast majority of studies have been conducted by administering the polyphenol at the
same time as an obesogenic diet. Under these experimental conditions, resveratrol has shown effective-
ness improving diet-induced excessive liver lipid accumulation. Data are scarce for studies carried out by
administering resveratrol under standard or energy-restricted feeding conditions. In this regard, while
resveratrol retains its effectiveness, ameliorating hepatic steatosis under standard feeding conditions, such
an effect has not been reported for the administration of the polyphenol under energy restriction. With
regard to clinical trials, in the majority of them, resveratrol did not show its effectiveness in improving
hepatic steatosis. This lack of effect could be due to significant differences in the experimental procedures
(mainly the length of the experimental period). The relevance of liver fat content at the baseline should
also be considered. Altogether, there is no sufficient scientific support so far for proposing resveratrol as a
tool for hepatic steatosis treatment.
1. Introduction
Liver diseases are among the leading mortality causes world-
wide in the last few decades. By the year 2010, it was estimated
that 4% of all deaths worldwide were due to major liver dis-
eases, such as cirrhosis and hepatocellular carcinoma.1 Non-
alcoholic fatty liver disease (NAFLD) comprises several hepatic
pathological conditions, characterised by excessive lipid
content, with or without inflammation and fibrosis (steatohe-
patitis and steatosis, respectively). The main concern with
NAFLD is the possibility to progress towards more harmful
stages (cirrhosis or hepatocellular carcinoma),2 as well as
being intimately related to other cardiometabolic alterations
such as type 2 diabetes, metabolic syndrome and heart
failure.3 Indeed, NAFLD is widely considered as the hepatic
manifestation of metabolic syndrome.4
Traditionally, the “double-hit” theory has been used to
explain the underlying processes resulting in NAFLD. In this
regard, liver triglyceride (TG) accumulation is considered as
the “first hit”, which causes damage in this organ, making it
more prone to progressing towards non-alcoholic steatohepati-
tis (NASH). As far as the “second hit” is concerned, this would
be comprised of oxidative stress, autophagy and inflammation,
contributing to further NASH progression.5 However, this
theory has been considered obsolete for explaining such a
complex process, and thus the “multiple-hit” theory has been
proposed as a more accurate one (Fig. 1). In this regard,
insulin resistance (common in overweight and obese people)
would be triggering the whole process. Thus, impaired adipose
tissue insulin signalling, which increases adipose tissue lipoly-
sis, and adipose tissue inflammation,6,7 results in excessive
free fatty acids (FFA), which, in turn, are deposited in the liver.
Along with the aforementioned hepatic lipid accumulation,
the high levels of FFA, cholesterol and lipid metabolites
present in the liver induce lipotoxicity. Therefore, mitochon-
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drial dysfunction occurs, which in turn enhances oxidative
stress and reactive oxygen species (ROS) production, while
mechanisms of endoplasmic reticulum stress are also acti-
vated. Moreover, the alterations in gut microbiota result in
greater intestinal permeability and the release of pro-inflam-
matory cytokines such as interleukin 6 (IL-6) and tumour
necrosis factor α (TNF α).8 It is important to point out that,
whereas this sequence of metabolic alterations is found in sub-
jects who show NAFLD associated to obesity, there are also
genetic types of NAFLD such as that associated to polymorph-
isms in PNPLA3 and TM6SF2, which are not related to altered
TG and HDL-cholesterol levels and insulin resistance.9
Hepatic steatosis is the most benign form of NAFLD, as well
as the most common one. This hepatic alteration can be diag-
nosed chemically when intrahepatic TG accumulation is
greater than 5% of liver weight, or by histologic analysis of the
tissue, when 5% or more of the hepatocytes show TG accumu-
lation.5 Even though hepatic steatosis by itself does not rep-
resent a major threat to health, its potential to evolve into
more detrimental liver alterations make its treatment
necessary.
Since hepatic steatosis is mainly present in patients
suffering from obesity and/or type-2 diabetes, hypocaloric
diets, along with interventions devoted to enhancing physical
activity, represent the cornerstone for its treatment. The effec-
tiveness of energy-restricted diets in improving hepatic steato-
sis has been extensively described in both, preclinical
studies10–13 and clinical trials.14,15 However, the main limit-
ation of this kind of treatment is the low adherence that is
often achieved, mainly due to stress, emotional factors, or
difficulties in modifying dietary habits.
In this scenario, scientific community has been looking for
alternatives that could improve the outcomes of the
approaches currently used for hepatic steatosis treatment. In
recent years, much attention has been paid to phenolic com-
pounds, a wide and heterogeneous group of plant-derived
molecules that are naturally present in a variety of foodstuffs
within our diet. Among them, resveratrol (3,5,4′-trihydroxy-
trans-stilbene) has been one of the most studied ones (Fig. 2).
This phenolic compound has been proposed as an energy
restriction mimetic molecule (mimicking the effects of such
dietary approach, without limiting the caloric intake), and
thus has been extensively studied as a potential anti-
obesity16–18 and anti-hypertensive agent.19 In addition, resvera-
trol has also shown effectiveness in the amelioration of further
health alterations, such as hepatic steatosis. In this regard,
this phenolic compound has been reported to modulate and
reduce hepatic lipid content in rodents under different experi-
mental conditions,10,12,13,17,20–50 as well as in humans
suffering from this liver condition;51–53 despite, in the case of
humans, the effects of resveratrol are not so clear. In none of
the studies included in this review significant reductions in
Fig. 1 Impaired WAT insulin sensitivity induces alterations in lipolysis, resulting in an excessive FFA release. On entering the liver, the excess FFA pro-
duces lipotoxicity and mitochondrial dysfunction, which result in enhanced oxidative stress, ROS production, and decreased FA oxidation.
Consequently, enhanced hepatic TG synthesis occurs, resulting in a greater TG content in the liver. Increased insulin, glucose and fructose levels will
also be triggering de novo lipogenesis, further enhancing hepatic TG synthesis. Finally, alterations in gut microbiota composition will lead to a
greater release of proinflammatory factors to the bloodstream, which once in the liver will trigger inflammation-related pathways. FFA: free fatty
acids, HSL: hormone-sensitive lipase, IL-6: interleukin 6, IR: insulin resistance, ROS: reactive oxygen species, TG: triglyceride, TNFα: tumour necrosis
factor α, VLDL: very low-density lipoprotein, WAT: white adipose tissue.
Fig. 2 Chemical structure of resveratrol (3,5,4’-trihydroxy-trans-
stilbene).
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hepatic lipid content after resveratrol administration were
reported; however, in some of them, resveratrol-derived
improvements in NAFLD were observed. In this regard, it is
important to highlight that the studies were probably too short
to show an effect on hepatic lipid composition. In some
studies, the doses used may not have been the most effective
ones.54
This review aims to analyze the effects of resveratrol in
different models of hepatic steatosis, as well as under different
feeding conditions (overfeeding, normal feeding and caloric
restriction). The effectiveness of this phenolic compound in
clinical studies is also revised.
2. Effects of resveratrol on hepatic
steatosis in preclinical studies
conducted under overfeeding
conditions
The use of overfeeding conditions is a commonly applied
experimental procedure in studies in which hepatic steatosis
induction is looked for. This feeding pattern is based on the
usage of obesogenic diets, which generally are high-fat diets
that may also contain high amounts of sugars (such as sucrose
or fructose). It must be taken into account that in the studies
using this experimental procedure, the polyphenol is usually
administered at the same time than the obesogenic diet, and
thus the preventive effect that the bioactive compound may
exert on this hepatic condition is studied.
In the vast majority of the studies available in the literature
that have been conducted using this experimental procedure,
and are included in this review article, resveratrol has been
shown to be effective in reducing the hepatic lipid content, in
both mice10,17,20–22,24,25,27–34,55 and rats12,35,37–41,56 (Table 1). In
these studies, besides this hepatic lipid-lowering effect, resveratrol
has also shown to be effective in improving other parameters
related to hepatic steatosis, such as blood glucose, serum lipids
and transaminase levels, as well as liver oxidative status. It is worth
emphasizing that these effects have been observed when using
diets with a lipid content in a broad range (from 20 to 60% of
energy as fat), resveratrol doses also in a broad range (from 15 to
400 mg per kg body weight per day) and with different treatment
period lengths (from 4 to 20 weeks). With regard to the dose, there
is no consensus regarding the existence of a dose–response effect
of resveratrol. Thus, while in some studies the high dose of the
compound was the most effective one,10 in others the low dose
induced greater effects20 or no differences were described among
the tested doses at all.24,37
In a reduced number of studies, resveratrol administration
did not induce beneficial effects on hepatic steatosis. In one
such study, conducted by Montero et al.,26 3-month-old male
C57BL mice were fed a hypercaloric diet (60% of energy from
fat) supplemented or not with resveratrol (0.025% w/w) for
12 months. When liver sections were analyzed by hematoxy-
lin–eosin (H&E) staining, no differences in lipid content were
found after 6 or 12 months in comparison to animals fed the
hypercaloric diet alone. Although the authors did not suggest
an explanation for this lack of effect, the selected dose (signifi-
cantly lower in comparison to doses used in other studies)
cannot be ruled out as the reason justifying this fact. In a
study from our group, carried out in 6-week-old male Wistar
rats fed an obesogenic diet (24% of energy from fat and 20%
of energy from sucrose) supplemented or not with 15 mg per
kg body weight per day of resveratrol for 6 weeks, we did not
observe differences in liver weight or hepatic lipid content (TG
and cholesterol) between resveratrol-treated and untreated
rats. In that study, in contrast to that observed in other studies
from our group, only one metabolic pathway (de novo lipogen-
esis) was affected by resveratrol. We considered that this effect
was not enough to reduce the hepatic lipid content.57
To understand the mechanisms of action involved in the
beneficial effects that resveratrol exerts in hepatic steatosis
under overfeeding conditions, different metabolic pathways
have been studied. In this regard, several studies have reported
a resveratrol-mediated reduction in hepatic de novo lipogenesis
by measuring the expression and/or activation of fatty acid
synthase (FAS) and acetyl-CoA carboxylase (ACC), the two main
enzymes involved in this process. Other authors have also
studied the effect of the polyphenol on fatty acid oxidation, a
process that may also underlie the lipid-lowering effect shown
by the compound. Enhanced activity of carnitine palmitoyltrans-
ferase 1 (CPT1), which is the enzyme regulating the entrance of
long-chain fatty acids into the mitochondria for their sub-
sequent β-oxidation, has been described in the animals receiv-
ing resveratrol. Several studies have also shown increased acti-
vation of 5′AMP-activated protein kinase (AMPK) along with a
greater expression of sirtuin 1 (SIRT1) after resveratrol adminis-
tration. In this regard, it is well known that SIRT1 is directly
related to mitochondrial synthesis, which in turn may explain
the enhanced hepatic CPT1 activity reported in resveratrol-
treated animals. As far as AMPK is concerned, besides being
involved in cell energy status regulation by activating adenosine
triphosphate (ATP)-producing pathways, its activation also
affects the de novo lipogenesis by inhibiting ACC (Fig. 3).
Besides the effects described for resveratrol in these path-
ways, some authors have also reported increased activity of
antioxidant enzymes, decreased lipid peroxidation and
immune cell infiltration, or enhanced autophagy in the liver of
the animals treated with the polyphenol, all of them mecha-
nisms that may contribute to alleviating the excessive hepatic
lipid accumulation due to overfeeding conditions. In addition
to these mechanisms of action, it has also been proposed that
some of the beneficial effects described for resveratrol may
occur through the modulation induced by the polyphenol in
gut microbiota composition.58 In this regard, in the study con-
ducted by Qiao et al.,27 male Kunming mice were fed a high-
fat diet (50% of energy from fat) and supplemented or not
with resveratrol (200 mg per kg body weight per day) for 12
weeks. At the end of the experimental period, the staining of
liver sections (Oil red O staining) revealed that the severe stea-
tosis observed in the non-treated animals was prevented in the
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animals receiving the polyphenol. As far as gut microbiota is
concerned, lowered abundances of the Lactobacillus and
Bifidobacterium groups, as well as increased abundance of
Lactobacillus faecalis were found in the non-treated high-fat
diet-fed animals. In the case of the group treated with resvera-
trol, these changes were reverted. The lowered
Bacteroidetes : Firmicutes ratio values found in the non-treated
animals were significantly increased in the group receiving the
polyphenol. Similar results were reported in the study con-
ducted by Yin et al.,34 in which 8–12 weeks-old male C57BL/
6 mice were fed a high-fat diet (60% of energy from fat) sup-
plemented or not with resveratrol (0.4% content in the diet,
w/w) for 12 weeks. At the end of the experimental period,
resveratrol effectively reduced the hepatic lipid content in the
treated animals when compared to the non-treated ones. With
regard to microbiota, the authors reported that at the phylum
level, the mice treated with resveratrol had a greater abun-
dance of Bacteroidetes, while the abundances of Firmicutes and
Proteobacteria were significantly decreased. Consequently, the
Bacteroidetes : Firmicutes ratio value was significantly greater in
the resveratrol-treated group when compared to the animals
that only received the high-fat diet. In addition, resveratrol
also reverted the increases in the abundance of some genera
(such as Oscillospira, Ruminococcus and Akkermansia) observed
in the non-treated high-fat diet fed animals. Interestingly, in
the same study, the faecal samples of the animals in the two
aforementioned groups were used to carry out faecal trans-
plants. Briefly, the faecal transplants from the non-treated and
resveratrol-treated animals were given to two additional groups
of mice that were then fed a high-fat diet for 8 additional
Table 1 Preclinical studies where resveratrol is administered under overfeeding conditions
Author Animal model Diet
Increase in
dietary




Baur et al. (2006)17 1-Year old-male C57BL/6NIA
mice





60% of energy from fat +50% 0.2 or 0.4% in the diet
(w/w)
Yes
Cho et al. (2012)21 4-Week-old male C57BL/6J
mice
40% of energy from fat +28% 0.02 or 0.04% in the diet
(w/w)
Yes
Jeon et al. (2012)21 4-Week-old male C57BL/6N
mice





58% of energy from fat +45.5% 30 mg kg−1 d−1 Yes
Andrade et al.
(2014)23,55
4-Week-old FVB/N male mice 61% of energy from fat +53% 30 mg kg−1 d−1 Yes
Choi et al.
(2014)24,25
Pathogen-free male ICR mice 59% of energy from fat No specified 15 or 45 mg kg−1 d−1 Yes
Jeon et al. (2014)25 4-Week-old male apoE-
deficient mice
20% of energy from fat
(corn oil and lard)





60% of energy from fat +50% 0.025% in the diet (w/w) No
Qiao et al. (2014)27 Male Kunming mice 50% of energy from fat +40% 200 mg kg−1 d−1 Yes
Nishikawa et al.
(2015)28
6 and 7-week-old C57BL/
6 mice
50% of energy from fat +46.2% 0.2% in the diet (w/w) Yes
Tian et al. (2016)29 4-Week-old C57BL/6 mice 60% of energy from fat Not specified 30 mg kg−1 d−1 Yes
Zhou et al. (2018)30 4–6 Weeks-old male C57BL/
6 mice
60% of energy from fat Not specified 400 mg kg−1 d−1 Yes
Cheng et al. (2019)31 6-Week-old male C57BL/
6 mice
60% of energy from fat +50% 100 mg kg−1 d−1 Yes
Teng et al. (2019)32 6 Weeks-old male C57BL/6J
mice
60% of energy from fat,
mainly from lard
+50% 200 mg kg−1 every 2 days Yes
Hosseini et al.
(2020)33
6 Weeks-old male C57BL/
6 mice
55.9% of energy from fat +45.9% 0.4% resveratrol in the
diet (w/w)
Yes
Yin et al. (2020)34 8–12 Weeks-old male C57BL/
6 mice
60% of energy from fat +50% 0.4% resveratrol in the
diet (w/w)
Yes
Shang et al. (2008)35 Male Wistar rats 59% of energy from fat Not specified 100 mg kg−1 d−1 Yes
Poulsen et al.
(2012)36
8-Week-old male Wistar rats 60% of energy from fat +50% 100 mg d−1 Yes
Xin et al. (2013)37 Adult male Wistar rats 54% of energy from fat +44% 50 or 100 mg kg−1 d−1 Yes
Arias et al. (2015)57 6-Week-old male Wistar rats 20% of energy from sucrose
and 24% of energy from fat
No standard
diet
15 mg kg−1 d−1 No
Pan et al. (2015)38 6-Week-old male Sprague-
Dawley rats
45% of energy from fat +35% 100 mg kg−1 d−1 Yes
Ding et al. (2017)12 8-Week-old male Wistar rats 41.3% of energy from fat +27.6% 200 mg kg−1 d−1 Yes
Badi et al. (2019)39 Adult Wistar rats 60% of energy from fat +50% 20 mg kg−1 d−1 Yes
Chen et al. (2019)40 2 Month-old male Sprague
Dawley
60% of energy from fat +50% 15 mg kg−1 d−1 Yes
Huang et al.
(2020)41
8–9 Weeks-old male Sprague-
Dawley rats
45% of energy from fat +35% 100 mg kg−1 d−1 Yes
ICR: institute of cancer research.
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weeks. At the end of the experimental period, the hepatic lipid
content in mice receiving the faecal transplant from the resver-
atrol-treated animals was significantly lower in comparison
with animals receiving the faecal transplant from non-treated
animals. The authors concluded that the hepatic lipid-lower-
ing effects shown by resveratrol in the high-fat diet-fed mice
may be related to the changes induced by the polyphenol in
the gut microbiota composition.
Based on the results reported in the studies included in this
section, it seems that resveratrol administration is an effective
approach for totally or partially preventing hepatic steatosis
induced by a feeding pattern in which energy intake surplus
occurs. Nevertheless, although beneficial effects have been
obtained by using this treatment protocol, due to obvious ethical
reasons, it would not be suitable for application in humans.
Allowing people to maintain an unhealthy dietary pattern and to
advise them to use resveratrol supplementation to avoid the devel-
opment of hepatic steatosis is not advisable.
3. Effects of resveratrol on hepatic
steatosis in preclinical studies
conducted under standard feeding
conditions
Few studies have analyzed the effects of resveratrol on liver
steatosis under standard feeding conditions. The experimental
procedure commonly used in these studies is as follows:
animals are firstly fed an obesogenic/steatotic diet and then,
once hepatic steatosis has been established, animals are
switched to a standard feeding pattern (using chow or stan-
dard semi-purified diets) and treated with resveratrol. With
this experimental design, the usefulness of resveratrol for
hepatic steatosis treatment was analyzed. This is a scenario
closer to that used in clinical studies.
Under this feeding pattern, significant decreases in liver
lipid content have been reported in studies carried out in
mice42 and rats13,41 (Table 2). The hepatic lipid-lowering effect
of resveratrol was observed when different doses of resveratrol
(from 30 to 100 mg per kg body weight per day) or treatment
period lengths (from 4 to 8 weeks) were used. Besides lower
hepatic lipid content, decreased plasma TG and transaminase
levels were also described in the animals treated with the
polyphenol.
With regard to the mechanisms of action involved in the
aforementioned effects, in the study carried out by our group
in 6-week-old male Wistar rats fed a high-fat high-sucrose diet
(45% of energy as fat and 13% of energy as sucrose) for 6
weeks, and then switched to a standard diet (16% of energy as
fat) supplemented or not with 30 mg per kg body weight per
day of resveratrol for 6 additional weeks, a significant
reduction in the protein expression of the fatty acid transport
protein 5 (FATP5) was reported in the livers of animals receiv-
ing the polyphenol. This effect suggests a resveratrol-mediated
reduction in fatty acid uptake. Moreover, greater CPT1 and
Fig. 3 Under overfeeding conditions, RSV reduces hepatic TG content through various mechanisms of action. Firstly, hepatic FA uptake is blunted
through the reduction of FATP5 expression, which results in lower disposal of FA for TG synthesis. RSV also inhibits enzymes involved in de novo
lipogenesis (ACC and FAS), decreasing FA availability for TG synthesis. Besides these effects, resveratrol also enhances FA oxidation by increasing
mitochondrial biogenesis (acting through the AMPK/SIRT1/PGC1α axis) and mitochondrial FA oxidation (activating CPT1). Finally, RSV also induces a
greater activation of MTP, resulting in increased TG release from the liver to the plasma, thus lowering the hepatic TG content. Ac CoA: acyl CoA,
ACC: acetyl-CoA carboxylase, AMPK: 5’AMP-activated protein kinase, CPT1: carnitine palmitoyltransferase 1, CS: citrate synthase, FA: fatty acids,
FATP5: fatty acid transport protein 5, Mal CoA: malonyl CoA, MTP: microsomal triglyceride transfer protein, PGC1α: peroxisome proliferator-acti-
vated receptor gamma coactivator 1-α, ROS: reactive oxygen species, RSV: resveratrol, SIRT1: sirtuin 1.
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citrate synthase (CS) activities, as well as enhanced AMPK
phosphorylation and decreased peroxisome proliferator-acti-
vated receptor gamma coactivator 1-α (PGC1α) acetylation were
observed in the rats treated with resveratrol, suggesting an
increase in fatty acid oxidation. Altogether, these metabolic
modifications lead to a lower fatty acid availability for TG syn-
thesis. The enhanced activity of the microsomal triglyceride
transfer protein (MTP) was also described in these same rats,
which pointed towards an increased TG delivery from liver to
plasma (Fig. 3).13
Similar results have been recently reported in the study con-
ducted by Huang et al.41 in which 8–9-week-old male Sprague
Dawley rats were firstly fed a high-fat diet (45% of energy from
fat) for 8 weeks and then switched to a standard diet (10% of
energy from fat) and treated or not with 100 mg per kg body
weight per day of resveratrol for 8 additional weeks. In this
case, the decrease in hepatic lipids was accompanied by
enhanced CPT1a activity and greater AMPK activation. The
authors also reported a decrease in both FAS protein
expression and ACC activation, suggesting that under these
experimental conditions, resveratrol also diminished de novo
lipogenesis. Moreover, it was also observed that the reductions
induced by the high-fat diet in the total anti-oxidative capa-
bility, the activities of antioxidant enzymes superoxide dismu-
tase (SOD) and catalase (CAT), as well as in the activities of
mitochondrial complexes I and IV were totally reverted by
resveratrol treatment.
Based on the data reported in these studies, resveratrol is
effective at reducing excessive hepatic lipid accumulation
when administered under standard feeding conditions to
animals that were previously fed obesogenic diets, and can
consequently treat liver steatosis.
Other studies aimed at managing fatty liver have been con-
ducted in animals with genetically induced hepatic steatosis
and fed standard diets. In this regard, the excessive hepatic
lipid accumulation occurs as the result of the genetic back-
ground of the animals, instead of being a matter of dietary
conditions. One such animal model is the KKAy mice, which
are used for research in obesity and/or metabolic disorders.
This animal model was used in the study carried out by Zhu
et al.,43 in which 8-week-old male KKAy were fed a standard
diet supplemented or not with two resveratrol doses (2 and 4 g
per kg diet), for 12 weeks. Decreased hepatic lipid content was
observed at the end of the experimental period, with no differ-
ences in both doses. In contrast, serum TG and FFA levels
were only decreased in the group receiving the highest dose.
Besides the liver lipid-lowering effect, decreased serum malon-
dialdehyde (MDA) and increased SOD levels were observed in
the animals treated with the polyphenol. When the hepatic oxi-
dative status was studied, the authors found that both resvera-
trol doses similarly decreased the levels of ROS, although
enhanced antioxidant enzyme activities were only observed in
the group treated with the highest dose. Finally, the results
also demonstrated that resveratrol effectively enhanced the
expression of SIRT1 and the activation of AMPK, suggesting
that resveratrol also activated ATP-producing pathways in the
livers of these animals.
Another genetic model of hepatic steatosis is the obese
Zucker rat ( fa/fa), which is characterized by a constant
accumulation of body fat throughout their life, and thus con-
sidered as a well-characterized model of NAFLD.59 Using this
experimental model, Rivera et al.44 carried out a study in
which obese male Zucker rats ( fa/fa) were fed a standard diet,
supplemented or not with 10 mg per kg body weight per day of
resveratrol (administered by oral gavage), for 8 weeks. The
enhanced hepatic TG and cholesterol contents found in the
non-treated animals were significantly decreased by resveratrol
administration. Similarly, the blood glucose and insulin levels
in the animals receiving the polyphenol were significantly
lowered in comparison with the non-treated animals. When
the potential mechanisms of action were analyzed, the authors
found that resveratrol significantly decreased the activity of
ACC, while that of AMPK increased, suggesting that the treat-
ment not only inhibited de novo lipogenesis but also activated
catabolic pathways devoted to energy production. The authors
concluded that chronic resveratrol administration effectively
improves the metabolic syndrome features that are present in
obese Zucker rats.
Subsequently, our group addressed a study in the same
animal model. Obese male Zucker ( fa/fa) rats were fed a stan-
Table 2 Preclinical studies where resveratrol is administered under standard feeding conditions (dietary and genetic models of steatosis)
Author Animal model Diet Resveratrol dose
Improvement in hepatic
steatosis







Standard diet (16% lipid, 20% protein,
64% carbohydrates)





Chow diet (10% of energy from fat) 100 mg kg−1 d−1 Yes
Zhu et al. (2014)43 8-Week-old male KKAy
mice
Standard diet 2 or 4 g kg per diet Yes
Rivera et al. (2009)44 13-Week-old male obese
Zucker rats ( fa/fa)




Zucker rats ( fa/fa)
Standard diet 15 or 45 mg kg−1 d−1 Yes
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dard diet and supplemented or not with 15 or 45 mg per kg
body weight per day of resveratrol (administered through an
orogastric catheter) for 6 weeks. In this case, resveratrol treat-
ment also resulted in a significant reduction in hepatic lipid
content that was irrespective of the dose. Similar results were
observed regarding serum levels of FFA. The activities of CPT1
and acyl-coenzyme A oxidase (ACO), both enzymes involved in
fatty acid oxidation, were significantly enhanced in the livers
of rats receiving resveratrol. Finally, both resveratrol doses
induced a significant reduction in the hepatic levels of thio-
barbituric acid reactive substances (TBARS), although the
overall redox status was more markedly improved in the group
receiving the highest dose.45
According to the reported results, it seems that resveratrol
at a dose in the range of 10–45 mg per kg body weight per day
is also effective at reducing genetically-induced excessive
hepatic lipid accumulation. The effects induced by the poly-
phenol were at least partially driven by enhanced fatty acid oxi-
dation and improved hepatic oxidative status.
4. Effects of resveratrol on hepatic
steatosis in preclinical studies
conducted under energy restriction
Energy restriction, along with increased physical activity, is the
non-pharmacological strategy commonly used for obesity treat-
ment. It is well-known that besides this anti-obesity effect,
energy restriction also reduces liver lipid content, thus ameli-
orating hepatic steatosis, not only in rodent models showing
diet-induced or genetic liver steatosis,10–12,60 but also in clini-
cal trials.14,15 Despite the health benefits of this dietary
approach for hepatic steatosis management, the low adherence
of many subjects to this protocol limits its effectiveness as a
therapeutic tool in humans. In this context, since resveratrol
has been considered an energy restriction mimetic molecule,
the combination of both approaches (energy restriction and
resveratrol supplementation) could represent an alternative to
overcome the aforementioned limited adherence to restricted
diets because the same effect might be achieved by using less
restrictive diets. Nevertheless, data regarding studies con-
ducted under energy restriction feeding conditions aimed to
determine the effects of resveratrol are really scarce.
In our group, we have addressed the only two reported
studies carried out under these feeding conditions. In the first
one, 6-week-old male Wistar rats were fed a high-fat high-
sucrose diet (HFHS) for 6 weeks to induce obesity and liver
steatosis.50 Then, the animals were switched to a standard diet
and submitted to a 25% energy restriction supplemented or
not with resveratrol (30 mg per kg body weight per day), for 2
additional weeks. At the end of the experimental period, no
differences were observed between both groups in terms of
final body weight or liver parameters (weight, hepatic index
and TG content). We were surprised by these results since
resveratrol had shown effectiveness in improving hepatic stea-
tosis under overfeeding and normal feeding conditions, and
thus, we hypothesized that this polyphenol would also be able
to increase the beneficial effects induced by energy restriction.
To explain this lack of effect, we proposed that the effects pro-
duced by energy restriction were strong enough to mask those
of resveratrol. It is important to point out that in this study, we
chose a 25% energy restriction because it is commonly used in
interventions conducted in humans. To avoid this possible
bias, in a second study we used a similar experimental pro-
cedure, maintaining the dose of resveratrol but using a lower
energy restriction percentage (−15%) and a longer experi-
mental period length (6 weeks).13 As in the first study, no sig-
nificant differences were appreciated between both experi-
mental groups submitted to the restricted diet, receiving the
polyphenol or not.
These results suggest that resveratrol is not an effective
approach to enhancing the liver’s delipidating effect induced
by energy restriction. By using the data obtained in our
studies, we can state that the effects induced by 30 mg resvera-
trol per kg per d are weaker than those induced by a 15%
energy restriction.
5. Effects of resveratrol on hepatic
steatosis in preclinical studies
conducted using other dietary models
In addition to the models of liver steatosis described in the
previous sections of this review, other models have also been
used in the studies devoted to analyzing the effects of resvera-
trol. One of these models is that described by Delzenne
et al.,61 consisting on the combination of a high carbohydrate-
fat free (HCFF) feeding and fasting/refeeding periods. Based
on this model, Bujanda et al.46 fed male Wistar rats a high
carbohydrate-fat free diet (80% of energy from starch) for 4
days, and then they fasted the animals for 3 additional days.
This procedure was repeated 4 times during the whole experi-
mental period. The experimental group treated with resveratrol
received the polyphenol at a dose of 10 mg d−1 and the control
group just received the vehicle. At the end of the experimental
period, H&E staining revealed lower fat infiltration in the livers
of the animals treated with resveratrol. Lower serum levels of
TNF-α and MDA were also found in the resveratrol-treated
group. As far as liver oxidative stress is concerned, enhanced
activities of SOD, CAT and glutathione peroxidase (GPx), as
well as decreased activity of nitric oxide synthase (NOS), were
reported by the authors in the animals receiving the polyphe-
nol. Altogether, these results suggest that in these animals, the
inflammatory and oxidative status were ameliorated by the
polyphenol.
Methionine choline-deficient diet (MCD) feeding is another
frequently used dietary model to induce hepatic steatosis. It is
based on the deficiency of methionine and choline, which are
essential for liver ß-oxidation and the production of very low-
density lipoprotein (VLDL).62 Indeed, the histological and mor-
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phological changes driven by this dietary approach in the liver
encompass steatosis, inflammation and aminotransferase
elevation.63 Ali et al.48 fed male Wistar rats a MCD diet for 28
days, following the same feeding pattern than that used by
Bujanda et al. (4 day ad libitum feeding followed by a 3 day
fast). During this experimental period, the rats were given
resveratrol (10 mg per kg body weight per day) or the vehicle
daily by the oral route. At the end of the experimental period,
the multifocal hepatocellular necrosis and inflammatory cell
infiltration, revealed by H&E staining in the non-treated rats,
were avoided in the group treated with resveratrol, which
showed a preserved liver architecture. In addition, lower serum
levels of transaminase, glucose, lipids and inflammatory
markers were found in the group receiving the phenolic com-
pound when compared to the non-treated steatotic rats.
Similarly, hepatic levels of oxidative stress markers were also
significantly decreased by the polyphenol treatment.
Another model is that in which early weaning programming
is used to induce different metabolic disturbances. It has been
described that this procedure causes undernutrition for a
short period of time, programming the offspring for the devel-
opment of different metabolic alterations in the adult life.64
Based on this model, Franco et al.,47 shortened the lactation of
male Wistar rats for 3 days (18 days of lactation instead of 21).
The rats were then fed a standard diet for 150 days. At this
point, animals received resveratrol (30 mg per kg body weight
per day) or vehicle by oral gavage for 30 days and were fed the
same diet. At the end of the experimental period, the increased
content of TG found in the liver was lower in rats treated with
resveratrol than in the control rats. The microvesicular steato-
sis revealed by H&E staining in non-treated rats was signifi-
cantly ameliorated by resveratrol administration. Similarly,
resveratrol significantly prevented the increase in blood lipid
levels found in the non-treated animals, as well as those
observed in oxidative markers in both liver and blood.
Another approach commonly used to induce hepatic steato-
sis is high-fructose feeding. This sugar is characterized for
being highly lipogenic, resulting in increased TG and free fatty
acid accumulation in the liver and blood. El-Haleim et al.,49
fed two groups of adult male albino rats a normal chow diet
and provided them with fructose in drinking water (10%), for
12 weeks. During the last 4 weeks of the treatment (weeks 9 to
12), a group of rats was treated with resveratrol (70 mg kg−1
d−1). Lower liver index and TG content were observed at the
end of the experimental period in the animals receiving the
compound when compared to the non-treated ones. Similarly,
the histopathological examination of liver sections revealed
that resveratrol significantly decreased the average steatosis
area in comparison with the non-treated rats. The authors
reported that the polyphenol prevented most of the histopatho-
logical abnormalities observed in the livers of non-treated rats.
Additionally, lower serum TG levels and decreased hepatic
MDA content were also observed in the animals receiving
resveratrol.
The results reported in the studies included in this section
demonstrate that resveratrol is also effective in improving
hepatic steatosis induced by dietary models other than those
based on energy intake or genetic alterations. In this regard,
the beneficial effects exerted by the polyphenol are consistent
in a range of doses from 10 to 30 mg per kg body weight per
day (Table 3). Regarding the proposed mechanisms of action
underlying these beneficial effects, it seems that the polyphe-
nol mainly acts by reducing the hepatic oxidative stress
induced in these experimental models.
6. Effects of resveratrol in hepatic
steatosis in clinical studies
Several studies have been conducted in humans, which were
aimed at determining the effectiveness of resveratrol for
hepatic steatosis treatment (Table 4). In the eight reported
studies that have been included in this review52,53,65–70 all the
patients had diagnosed NAFLD at the beginning of the study.
Besides this common feature, the experimental procedures
used in these studies were significantly different among them,
not only regarding the used resveratrol dose (ranging from 50
to 3000 mg d−1), but also regarding the selected experimental
period length (from 8 weeks to 6 months) or patient character-
istics (age, sex or body mass index). In some of the studies, the
experimental groups received nutritional/lifestyle modification
advice besides resveratrol administration, making it more
difficult to identify the effects induced by the polyphenol
itself.
Compared to the results described in preclinical studies,
the effects of resveratrol in steatosis in humans are rather
Table 3 Preclinical studies in other dietary models of steatosis






Bujanda et al. (2008)46 Male Wistar rats HCFF diet (80% of energy from starch) 10 mg d−1 Yes
Franco et al. (2013)47 Male Wistar rats (early
weaned)
Standard diet 30 mg kg−1 d−1 Yes
Ali et al. (2016)48 Male Wistar rats (weanling) MCDD 10 mg kg−1 d−1 Yes
El-Haleim et al.
(2016)49
Adult male Albino rats Normal chow diet +10% fructose in drinking
water
70 mg kg−1 d−1 Yes
HCFF: high carbohydrate fat-free, MCDD: methionine choline-deficient diet.
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weak. None of the eight studies included in this review showed
significant reductions in the hepatic lipid content after resver-
atrol administration. In this regard, it should be considered
that the baseline liver fat content can play an important role in
subject responsiveness. Thus, in the study reported by
Kantartzis et al., where a large variability in this parameter was
observed (ranging from 0.09% to 37.55%), subjects with a very
high liver fat content at baseline showed a significant
reduction in hepatic steatosis after resveratrol treatment. In
contrast, this effect was not observed in subjects with a low or
moderately elevated baselina liver fat content.68 Despite the
lack of effect on liver lipid content, in some studies, resvera-
trol-derived improvements in NAFLD have been reported, even
though liver lipid content was not diminished. In this regard,
decreased levels of serum transaminases,52,53 lipids,53
glucose53 and inflammatory markers52 were observed. A
reduction in hepatic fibrosis was also described in one study,52
although without reaching statistical significance when com-
pared to the non-treated group.
The apparent discrepancies among the results obtained in
animal studies and those reported in clinical trials may be due
to differences in the experimental procedures. There are 3 vari-
ables that may explain this lack of consensus, which are the
used resveratrol doses, the selected experimental period length
and the additional interventions (besides resveratrol adminis-
tration) that were used in some of the clinical trials.
Concerning the resveratrol doses, based on the Reagan-Shaw
formula,71 which is commonly used to translate the doses
used in animal studies to humans, it can be demonstrated
that the doses selected in the clinical trials are in the range of
those shown to be effective in ameliorating hepatic steatosis in
rodent models. Thus, it seems that the lack of effect reported
in humans is not due to the use of lower doses of resveratrol.
As far as the experimental period length is concerned, it must
be taken into account that the lifespan in rodents is shorter
than in humans. Consequently, the influence of several weeks
of treatment in rodents can be more effective in these small
animals than in humans. As such, it has been reported that in
adult rats one day is equivalent to 34.8 human days,72 a corre-
lation that is even greater for young rats. Based on the afore-
mentioned equivalence, the experimental periods used to test
the usefulness of resveratrol for hepatic steatosis treatment in
rats would range from 1044 to 4385 days in humans. This
observation may justify the lack of correlation between results
obtained using rodent models and those obtained in human
studies. Indeed, resveratrol-derived hepatic lipid content
reductions in humans cannot be ruled out if such treatment
periods were used. Finally, in some studies, lifestyle modifi-
cation interventions were introduced to the patients of the
treated and placebo groups: dietary advice, encouraging par-
ticipants to acquire/maintain healthy dietary habits52,69 and/or
encouraging the practice of regular physical exercise.52 In one
study, participants maintained a low-fat diet under the super-
vision of a nutritionist throughout the whole experimental
period.70 These lifestyle modifications could have masked the
potential effects derived from resveratrol administration, as
occurred in rats fed an energy-restricted diet and sup-
plemented with resveratrol.13,50
8. Concluding remarks
After analyzing the reported results, it can be stated that pre-
clinical studies demonstrate the ability of resveratrol to prevent
liver steatosis induced by different unbalanced dietary pat-
terns. Moreover, when liver steatosis is already established,
this phenolic compound is useful for reducing this lipid altera-
tion, meaning that it could represent a new tool for fatty liver
treatment, although its effectiveness is lower than that of
energy restriction. These beneficial effects are mainly due to
the reduction in de novo lipogenesis, the increase in fatty acid
oxidation, the increase in autophagy and the decrease in oxi-
dative stress. The results reported concerning the effects of
resveratrol on gut microbiota composition should also be
taken into account, since the modulation induced by the poly-
phenol (restoration of the diversity and the equilibrium of gut
microbiota), especially in animals that have been fed obeso-
genic diets causing dysbiosis, seems to be related to the afore-
mentioned beneficial effects.
Table 4 Clinical studies
Author Subject Additional interventions Resveratrol dose
Improvement in
hepatic steatosis
Chachay et al. (2014)65 Obese or overweight men with NAFLD No 3000 mg day−1 No
Faghihzadeh et al. (2014)52 Subjects with NAFLD Yes (dietary and physical
activity advice)
500 mg day−1 Yes
Chen et al. (2015)53 Subjects with NAFLD No 600 mg day−1 Yes
Heebøll et al. (2016)66 Overweight subjects with NAFLD No 1.5 g day−1 No
Poulsen et al. (2018)67 Obese or overweight, non-diabetic
subjects with NAFLD
No 1.5 g day−1 No
Kantartzis et al. (2018)68 Obese or overweight men with NAFLD No 150 mg day−1 No
Asghari et al. (2018)69 Overweight subjects with NAFLD Yes (dietary advice) 600 mg day−1 No
Theodotou et al. (2019)70 Subjects with NAFLD Yes (dietary advice) 50 and 200 mg day−1 No
NAFLD: non-alcoholic fatty liver disease.
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In contrast, resveratrol administration seems not to be
effective when provided under energy restriction conditions,
showing that it cannot be considered as a complementary tool
to hypocaloric diets in the treatment of liver steatosis. The
reason for this lack of effect is not clear but it could be hypoth-
esized that the strong effect of energy restriction masks the
milder effect of resveratrol.
After determining the beneficial effects of resveratrol on
liver steatosis in rodents, the next step was to check whether
these effects are reproduced in humans. Unfortunately, this is
not the case since despite resveratrol treatment improving
several parameters related to this hepatic alteration, the
hepatic TG content did not decrease in the reported studies.
Several aspects can be considered to explain the lack of effec-
tiveness of this compound in humans, and among them, the
treatment duration seems to be a crucial aspect. Nevertheless,
more clinical studies are needed to definitely discard this treat-
ment option.
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